An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) announced a fireside chat with CEO Brian M. Culley scheduled for April 27, 2022, at 3:30 PM EST. The event will be hosted by Mayank Mamtani, Senior Analyst at B. Riley Securities, focusing on two new cell therapy programs stemming from the collaboration with Roche and Genentech for the RG6501 (OpRegen®) program.
Lineage specializes in developing allogeneic cell therapies, targeting unmet medical needs in significant markets.
Positive
None.
Negative
None.
Fireside Chat with B. Riley Research Analyst Scheduled for 3:30pm Eastern Time
Topics Will Include Two New Cell Therapy Programs Launched Following Roche and Genentech Partnership for RG6501 (OpRegen®) Program
CARLSBAD, Calif.--(BUSINESS WIRE)--
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today Brian M. Culley, Lineage’s Chief Executive Officer, will present at the B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference, in a fireside chat hosted by Mayank Mamtani, Managing Director, Senior Biotech Research Analyst and Group Head of Healthcare Research at B. Riley Securities, on Wednesday April 27th, 2022 at 3:30pm EST.
Interested parties can register to view both the live event and replay on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.
What is the purpose of the fireside chat scheduled for April 27, 2022, by LCTX?
The fireside chat aims to discuss two new cell therapy programs launched in partnership with Roche and Genentech, focusing on the RG6501 (OpRegen®) program.
Who is hosting the fireside chat for Lineage Cell Therapeutics on April 27?
The fireside chat will be hosted by Mayank Mamtani, the Managing Director and Senior Biotech Research Analyst at B. Riley Securities.
Where can I watch the LCTX fireside chat scheduled for April 27, 2022?
You can register to view the fireside chat live or as a replay on Lineage's website under the Events and Presentations section.
What are the new cell therapy programs discussed by LCTX's CEO?
The new cell therapy programs include developments from the OpRegen® program in collaboration with Roche and Genentech.
What is Lineage Cell Therapeutics focused on?
Lineage Cell Therapeutics focuses on developing allogeneic cell therapies for unmet medical needs, leveraging proprietary cell-based therapy platforms.
